Lyme disease is a chronic spirochetosis caused by Borrelia burgdorfen (4, 10, 23) . This bacterium is transmitted to humans by ticks of the genus Lxodes and occurs in temperate zones of the northern hemisphere, with epidemic foci in the United States and Europe. B. burgdorferi has two linear plasmid-encoded, lipid-modified outer surface proteins (Osps) of unknown function, OspA and OspB (2, 7, 8) , which exhibit geographic variation (24) , OspB being the more variable (3) . The chronic aspects of this disease suggest persistence of the spirochete in host tissues. In this regard, Osp variability may aid the spirochete in evading the immune response, thus prolonging the illness. Patients produce antibodies to the Osps late in the disease, if at all (12, 16) , but experimental animals develop a rapid and strong humoral response after intraperitoneal inoculation of B. burgdorfen (5) . The response in animals has been used in vitro to select for different types of antibody-resistant mutants, or escape variants, from strain B31, as a means of studying Osp variability (15, 21) . One immunoglobulin G monoclonal antibody (MAb) to OspB (CB2) and its Fab fragments destroyed high-passage strain B31 in vitro and selected for an escape variant (EvB-) that apparently did not express OspB. However, variant EvB-continued to express OspA and also expressed a new polypeptide of Mr 21 ,500 that was not recognized by the selecting MAb, CB2. The presence of OspA indicated that the entire 49-kb plasmid was not deleted (15) . In this report, we present evidence that the newly expressed Mr-21,500 protein of variant EvB-is a truncated form of OspB. In addition, we have identified a single C-terminal amino acid position in OspB which is necessary for its recognition by two MAbs.
The genes encoding OspA and OspB are located on a 49-kb linear plasmid (2) and are organized into an operon of -2.0 kb under the control of a common promoter (19) . The nucleotide sequence of the operon has been determined (7). We attempted to amplify the osp operon of variant EvB-by PCR to verify the presence of the ospB gene. For the DNA template, B. burgdorfien variant EvB-and high-passage strain B31, used to generate MAb CB2 and from which variant EvB-was selected, were grown as previously described (6) . B. burgdorferi pellets (10-ml culture washed twice in phosphate-buffered saline [pH 7.4], 40C, 7,000 x g, 10 min) were resuspended in 50 ,ul of 10 mM Tris-1 mM EDTA (pH 8.0) and heated in a 100°C water bath for 10 min. Cell debris was removed by centrifugation at 7,000 x g. Oligonucleotide primers flanking the entire 2.0-kb osp operon were based on the published sequence (7) (Fig. 1 ).
The ospB nucleotide sequences in variant EvB-and high-passage B31 were determined to investigate the apparent failure of variant EvB-to express OspB and to compare them to relevant segments of the prototype B31 ospB gene sequence (7) . PCR was used to amplify overlapping segments (300 to 500 bp) of the ospB gene of each strain. The oligonucleotide primers were based on the prototype sequence (7) and are shown in Table 1 . PCR-amplified DNA bands were excised from ethidium bromide-stained 0.8% agarose gels and purified (Magic PCR Preps; Promega Corp., Madison, Wis.). DNA was reamplified in triplicate by PCR and purified as before. Amplified and purified DNA was sequenced by use of fluorescence with the Taq DyeDeoxy Terminator Cycle sequence kit (Applied Biosystems, Inc., Foster City, Calif.) in conjunction with the Applied Biosystems model 373A DNA sequencing system. The resultant DNA sequences were identical to the sequence of ospB of the prototype (7), with a few notable exceptions, which are shown in Fig. 2A A) ; OspB, control BEP4 OspB excised from SDS-polyacrylamide gels; V8, cleavage products generated by V8 protease digestion of the excised OspB; V8 (2C2), cleavage products assayed for reactivity to MAb 2C2 by Western blotting. The smallest reactive fragment, fragment C (***), was selected for NH2-terminal amino acid sequence analysis, the results of which are shown at the bottom of panel B. (C) Schematic representation of the truncated OspB of variant EvB-and protease fragments A, B, and C in their presumed full length, on the basis of the N-terminal sequence and Mr all in relation to OspB of high-passage B31. N termini are on the left, and C termini are on the right. Arrowheads are used to depict protease fragments because C termini were not determined.
coded for the full-length OspB protein of 296 amino acids and with a deduced molecular weight of 31,739.
Another missense mutation, at np 1571 (T --G), resulted in a change from valine to glycine and was present in high-passage B31 and also in variant EvB-, although downstream from the premature termination codon. It is of interest that high-passage B31, in continuous cultivation in our laboratory since its initial isolation in 1982 (10) and subsequent cloning (1), has undergone over the years point mutations that have resulted in phenotypic changes from the first published sequence of this strain (7) .
Another MAb, 2C2, an immunoglobulin M MAb directed against OspB of B. burgdorferi BEP4 (14) , a low-passage strain isolated from the same geographic area as prototype B31, was not bactericidal for this strain or for B31, to which it did not react. Likewise, CB2 did not recognize strain BEP4. We sequenced ospB from BEP4 as described previously and compared the results with those for high-passage B31 and the prototype (7) to learn about the epitopes for both of these MAbs ( Fig. 2A) . With respect to the prototype sequence, BEP4 ospB differed at np 1571 (T --G), 1716 (T --C), and 1739 (A -* C). BEP4 did not differ from the published sequence at np 1510, as did high-passage B31 and variant EvB-. More importantly, for epitope definition, high-passage B31 and BEP4 differed at three np: 1510 (T --G), 1716 (T --C), and 1739 (A --C). The variation at np 1716 did not result in a change in primary amino acid structure and was not considered further. Since CB2 no longer recognized the truncated OspB of EvB-, its epitope may lie within the C terminus of the full-length protein of high-passage B31 and may be coded for by nucleotides downstream from the codon for the C-terminal amino acid of variant EvB-OspB. Variations at np 1510 and 1739 and the changes in amino acid sequence that they caused were both downstream from this point; therefore, either or both could be responsible for the differential reactivity of MAbs CB2 and 2C2 (Fig. 2B) .
To further map the epitopes of CB2 and 2C2, we treated B. burgdorferi OspB from B31 and BEP4 with Staphylococcus aureus V8 protease. Cleavage products were analyzed for reactivity to these MAbs by Western blotting (immunoblotting). For CB2, OspB from B31, in the form of a recombinant expressed in Escherichia coli, was lyophilized and resuspended in 25 mM ammonium acetate (pH 4.0). S. aureus V8 protease (Endoproteinase Glu-C; Boehringer Mannheim Biochemicals, Indianapolis, Ind.) was added at a concentration of 1 ,ug of enzyme to 20 ,ug of substrate. Incubations were done at 25°C. Proteolysis was stopped at 16 h by heating with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer at 100°C for 2 min. Epitope mapping of 2C2, because of its strain specificity (does not recognize B31), required the use of B. burgdorferi BEP4. BEP4 OspB was excised from SDS-polyacrylamide gels, and the gel slices were subjected to digestion by V8 protease according to the method of Cleveland et al. (11) . SDS-PAGE and Western blotting (12) and NH2-terminal amino acid sequencing (13) were done as previously de- scribed. Epitope mapping of CB2 yielded a nonreactive fragment (to CB2) of Mr 12,900 (fragment A) within the N terminus and a reactive fragment of Mr 9,300 within the C terminus (fragment B) (Fig. 3A and C) . Epitope mapping of 2C2 (with BEP4 OspB) yielded a reactive fragment of Mr 9,100 (fragment C) also located at the C terminus ( Fig. 3B  and C) .
Fragment B, from strain B31 and carrying the epitope for CB2, is a peptide approximately 86 amino acids in length. Using this information and the known amino acid sequence for prototype B31 OspB (7), we constructed a series of 11 overlapping synthetic peptides covering the C-terminal region of OspB containing fragment B to learn more about the epitope for CB2 (Fig. 4A) . The strongest reactive signal in a pin-bound enzyme-linked immunosorbent assay system (18) (data not shown) was associated with synthetic peptide T 
, representing amino acid residues 247 to 261. Preincubation of CB2 with peptide 8 produced a partial depletion of CB2 reactivity to OspB in Western blots, while preincubation with peptides 1 through 7 and 9 through 11 had no effect on the binding of CB2 to OspB of high-passage B31 (Fig. 4B) .
With respect to MAb CB2 and 2C2 epitopes, the variation at np 1510 was not within reactive fragment B or C.
However, the BEP4 variation at np 1739 (A --C; amino acid residue 253) resulted in a change from a lysine residue in high-passage B31 (and prototype B31) to a threonine residue in BEP4 (Fig. 2A) . The position of this variation mapped to V8 protease fragments B and C and to synthetic peptide 8 (Fig. 4B) . Since CB2 does not recognize BEP4 and 2C2 does not recognize high-passage B31, amino acid position 253 represents the only dissimilarity in OspB of the two strains that could account for the difference in MAb reactivity. Thus, the single amino acid at position 253, coded for by nucleotides 1738 to 1740 in both strains, is essential for the epitope and critical for recognition by each MAb.
NOTES 307
Clonal variation of OspB (9) , point mutations and recombination in this molecule resulting in chimeric epitopes (20) , and loss of OspB expression after prolonged in vitro cultivation (22) have been documented. The heterogeneity of OspB within and between strains isolated from close geographic areas, such as we have described here, as well as the ability to select variants with antibodies could be important components for the evasion of the B-cell response. If a patient's polyclonal antibody response to OspB were to be directed to the more variable areas of the C terminus of this molecule, the lack of serological reactivity to this antigen could reflect differences between the infecting strain and the strain chosen for the antigen in the serological assay. Lastly, OspB has been studied as a potential immunogen (17) . Given the ability to select escape variants with antibodies to this lipoprotein, it is questionable how suitable OspB is for this purpose.
The ospB sequence data for variant EvB-, high passage B31 and BEP4 are available from EMBL/GenBank under accession numbers X74808 (variant EvB-), X74809 (high passage B31), and X74810 (BEP4).
